We have examined the c-erbAfl thyroid hormone receptor gene in a kindred, G.H., with a member, patient G.H., who had a severe form of selective pituitary resistance to thyroid hormones (PRTH). This patient manifested inappropriately normal thyrotropin-stimulating hormone, markedly elevated serum free thyroxine (T4) and total triiodothyronine (T3), and clinical hyperthyroidism. The complete c-erbAfil coding sequence was examined by a combination of genomic and cDNA cloning for patient G.H. and her unaffected father. A single mutation, a guanine to adenine transition at nucleotide 1,232, was found in one allele of both these members, altering codon 311 from arginine to histidine. In addition, a half-sister of patient G.H. also harbored this mutant allele and, like the father, was clinically normal. The G.H. receptor, synthesized with reticulocyte lysate, had significantly defective T3-binding activity with a K. of -5 X 108 M-l. RNA phenotyping using leukocytes and fibroblasts demonstrated an equal level of expression of wild-type and mutant alleles in patient G.H. and her unaffected father. Finally, the G.H. receptor had no detectable dominant negative activity in a transfection assay. Thus, in contrast to the many other ,8-receptor mutants responsible for the generalized form of thyroid hormone resistance, the G.H. receptor appeared unable to antagonize normal receptor function. These results suggest that the arginine at codon 311 in c-erbA,6 is crucial for the structural integrity required for dominant negative function. The ARG-31 1-HIS mutation may contribute to PRTH in patient G.H. by inactivating a P-receptor allele, but it cannot be the sole cause of the disease. (J. Clin. Invest. 1993. 91:538-546.)
1. Abbreviations used in this paper: chloramphenicol acetyltransferase GRTH, generalized resistance to thyroid hormones; PCR, polymerase chain reaction; PRTH, pituitary resistance to thyroid hormones; TRAP, thyroid hormone receptor auxiliary proteins; TRE, thyroid levels of free thyroid hormones, and inappropriately normal thyrotropin-stimulating hormone (TSH) ( 1) . The majority of patients with this genetic syndrome have been found to have mutations in one allele ofthe c-erbA(3 thyroid hormone receptor gene on chromosome 3 (2, 3) . These mutations have been located in the thyroid hormone-binding domain (T3-binding domain) of the c-erbA( receptor ((-receptor) and result in mutant proteins with variable T3-binding affinity (4) (5) (6) (7) (8) (9) (10) (11) (12) .
Some mutant receptors such as those from kindreds Mf and S (4, 7) have an undetectable T3-binding affinity, whereas other mutant receptors such as those from kindreds CL and WR (8, 11 ) have reduced, but considerable T3-binding activity. The vast majority ofthese mutations lie within the penultimate and final exons of the receptor gene. Transient expression studies using these mutant receptors and thyroid hormone response elements (TREs) in heterologous promoters have demonstrated variable transactivating function that correlated with the T3-binding affinities of the mutant receptors ( 13, 14) .
The molecular basis ofGRTH is a dominant negative function conferred by the T3-binding domain mutations. These mutant receptors inhibit in some manner thyroid hormone action mediated by wild-type receptor from the remaining (3- receptor allele and from the two c-erbAa receptor ( 15 ) alleles on chromosome 17. The dominant negative activity resulting from the single allele c-erbA(3 mutations can be inferred from kindred G (16) (17) (18) (19) . The Refetoff patients with GRTH in kindred G have total absence of functional (-receptor. However, the obligate heterozygotes with only one normal (3-allele from kindred G are phenotypically normal (16) (17) (18) (19) . These genetic data taken together demonstrate that the mutant f(-receptors ofGRTH must act by antagonizing wild-type thyroid hormone receptor function and not solely through lack of activity ( 18, 19) . Furthermore, a patient from kindred S, the Bercu patient, has been described who is homozygous for a dominant negative (3-mutation (7, 20, 21 ) . The Bercu patient differs from the Refetoff patients and patients with heterozygous (3-muta- tions in that he is much more severely resistant to thyroid hormones. The Bercu patient, by way of comparison with the Re- fetoffpatients, demonstrates that a dominant negative (-recep- tor can inhibit at least some of the functions in man of the a-receptor. Finally, several transfection studies with the human mutant (-receptors support the notion ofdominant negative activity drawn from these genetic data ( 13, 14, 22) .
Selective pituitary resistance to thyroid hormones (PRTH) The (24) . DNA and RNA preparation. Leukocyte DNA was prepared from subjects as previously described (27) . Leukocyte RNA was obtained from the father (member 1, see Fig. 1 ). Blood obtained by phlebotomy was immediately centrifuged; the buffy cell layer was removed and placed in a 15-ml solution containing guanidinium isothiocyanate (5). This solution was frozen at -80'C until total RNA was recovered by centrifugation through cesium chloride (5) . Skin biopsies were performed on patient G.H. and her father. Primary fibroblast cell lines were established from both patients and total RNA was isolated by lysis in guanidinium isothiocyanate and centrifugation through cesium chloride (5).
Genomic cloning and sequencing. The genomic sequences of c-erbAB in patient G.H. and her father were examined using the same strategy that has been successfully applied in kindreds D, S, and CL (6) (7) (8) 28) . Multiple clones of exons 5-10 were sequenced using amplimers that have been previously published3 and the polymerase chain reaction (PCR) (3, 8) . The majority ofexon 4 at the NH2 terminus was cloned (codons 7-86) with amplimers 5'-GGGGATCCATCTGGT-TACCTTTACATTT-3' and 5'-GGGAATTCAACCCTTTAGAAA 2. The Refetoff mutation is an exception to this rule. GRTH was inherited recessively in kindred G ( 16 C-erbAfll cDNAs from patient G.H. and her father were cloned from fibroblast RNA in overlapping 5' and 3' portions. The 5'-cDNAs were synthesized using oligomer (5'-GGTCGCCACATGGGCT-TCGGTGACAGT-3', nucleotides 981-955) for first strand synthesis and the 3'-cDNAs were synthesized using oligomer (5'-GGAATTAT-GAGAATGAAT(T)CAGTCAGT-3', nucleotides 1,698-1,672) for first strand synthesis 940C, 1 min; 55°C, 30 s; 720C, 30 s. The amplified products were phenol/chloroform extracted, ethanol precipitated, and then submitted to HhaI digestion and gel electrophoresis. Construction ofthe G.H. receptor cDNA and T3-binding studies. A splicing overlap extension method was used to introduce the A-1232 base substitution into the wild-type human placental c-erbAfl cDNA (peA101) (30) as has been previously detailed (7, 8) . The portion of the recombinant cDNA, synthesized via PCR, was checked by sequencing to rule out an unintended mutation.
The G.H. receptor and wild-type human (3-receptor were synthesized with reticulocyte lysate using the reticulocyte lysate L-[335]methionine kit (Dupont-New England Nuclear; Wilmington, DE), (7, 8) . The T3-binding affinity measurements were done by saturation analysis with [123I]T3 and a nitrocellulose filter binding assay (7, 8) .
Transient transfection analysis ofwild-type and mutant human c-erbAl3 cDNAs. The assay for transactivation and dominant negative activity of mutant forms of c-erbA has been previously detailed (31) .
Briefly, the reporter plasmid MTV-TREir-CAT (CAT is chloramphenicol acetyltransferase) contains one copy of an inverted repeat (palindromic) thyroid hormone-responsive element (TREir) (AGGTCAT-GACCT) (31 ) cloned upstream of a mouse mammary tumor viral LTR-CAT vector lacking glucocorticoid response elements (32) . 6 ). After transfection, cells were incubated for 40 h without hormone or with 5 nM or 100 nM T3. CAT activity was quantitated using a thin-layer chromatography assay (34) . The amount of cell protein assayed and the incubation time were adjusted to yield 2 0. (24) . At presentation, her serum TSH was normal at 5.1 ,uU/ml, but the total T4 was 38.7 Mg/dl (normals, 5-13 ,g/dl), and the free T4 index was 58.5 (normals, 5-13). Graves' disease and pituitary tumor were excluded as causes of her hyperthyroidism (24) . Her serum T4 and T3 have remained in the hyperthyroid range since diagnosis, when off of therapy (Table I) . At the time of diagnosis, the patient's bone age was advanced, consistent with the diagnosis of PRTH (bone age of 14 yr, chronologic age of 12 yr) (24) . The patient's height and weight have remained within normal ranges for her age. The serum cholesterol of patient G.H. was below the normal range (24) , and her serum sex hormone-binding globulin was 146% above the mean ofthe other female members of kindred G.H., consistent with hepatic hyperthyroidism. In contrast to patient G.H., her father and mother (members 1 and 2, Fig. 1 ), halfsister (member 3, Fig. 1 ), and half-brother (member 4, Fig. 1 ) had no history of thyroid disease and had normal TSH and thyroid hormone levels (Table I) . They were clinically euthyroid on examination (Table II) .
A mutant c-erbAfl allele in patient G.H. and her unaffected father. Because of the severe PRTH of patient G.H., genomic DNA was first prepared from her leukocytes and the c-erbA(3 gene was sequenced using a previously described strategy (7, 8, 28) . Multiple clones of exons 5-10 (codons 90-457) from patient G.H. were sequenced, and a single authentic base substitution at nucleotide 1,232 in exon 9, a guanine to adenine, was found in 11 out of 17 independent clones (Fig. 2) . Surprisingly, two of six clones of exon 9 from the patient's unaffected father also contained the A-1232 base substitution. To completely evaluate the sequence of the 3 with the mutant allele. Blood specimens were also obtained from members 2, 3, and 4 ( Fig. 1) . The A-1232 base substitution eliminated an HhaI restriction site and a rapid screening method could, therefore, be used (Fig. 3) . This screening method revealed wild-type and A-1232 alleles in patient G.H., the father, and in the unaffected half-sister ofpatient G.H. The mother of patient G.H. and half-brother did not harbor the A-1232 allele. The half-sister was close to the same age as patient G.H. (Table I) (Fig. 4) . In three separate experiments, the T3-binding affinity of the mutant receptor was near the level of sensitivity ofthe filter-binding assay (-5 X I0 M-'). A representative T3-binding study with the in vitro mutant receptor and the human placental c-erbAll receptor is shown in Fig. 4 showing that the A-1232 base substitution was a mutation and not a polymorphism. Given the normal phenotypes ofthe father and the half-sister, we compared the level of expression of the mutant allele between patient G.H. and her father. RNA specimens from leukocytes and fibroblasts from the father were used to clone c-erbA#1 cDNAs, which were in turn screened for the presence of the G.H. mutation (Fig. 5) . This was also performed with o 0 *n 0 rlo 0 w n 0 rN. synthesized by reverse transcription and PCR amplification, was gel-purified and screened for mutant and wild-type sequences by the method shown in Fig. 3 . The 84-bp amplified product that was refractory to HhaI digestion contained the G.H. mutation; the two lower bands (54 and 32 bp) were generated from the population of wild-type cDNA. For comparative purposes, genomic DNA from patient 3, who had a mutant and a wild-type allele, and from a normal individual, Cl, were similarly screened for the G.H. mutation. C2 was a control amplification reaction without added DNA. (B) Fibroblast RNA was prepared from patient G.H. and her father, and cerbABl cDNAs (codons 150-448) were cloned by reverse transcription and PCR amplification. I-Ml aliquots from these PCR amplifications were further amplified 15 cycles with the screening amplimers in Fig. 3 and the products were subjected to HhaI digestion. The 84-bp band produced from mutant cDNA and the 54-and 32-bp bands produced from wild-type cDNA were seen in patient G.H. and her father. For comparative purposes, genomic DNA from patient G.H. (G.H. genomic) and from her unaffected half-brother with two normal alleles (4 genomic) were screened for the G.H. mutation as described in Fig. 3 . A and B are taken from ethidium-stained gels.
fibroblast RNA from patient G.H. To compare the proportion of mutant versus wild-type cDNA, genomic DNA specimens from wild-type individuals and heterozygous mutant carriers (half-sister or G.H.) were also amplified, screened with HhaI, and run on the same agarose gel (Fig. 5) . (The relative intensities on ethidium-staining of the mutant [84-bp] band vs. wildtype [54-bp, 32-bp] bands from the heterozygous, genomic specimens correspond to products produced from a 1:1 proportion ofmutant vs. wild-type DNA template.) The results shown in Fig. 5 indicate that the relative abundance of mutant to wild-type fibroblast cDNA, and therefore, mRNA, for both the father and patient G.H. was approximately 1:1. The father also showed equal abundance of mutant and wild-type mRNA in leukocytes. We infer from these data that the normal phenotypes ofthe father and half-sister cannot be explained by lack of expression of the G.H. allele but must result from a lack of dominant negative function of the mutant receptor.
The mutant G.H. receptor minimally transactivates but exhibits no dominant negative activity in transient transfection studies. The remarkable in vivo data were substantiated by transfection in HeLa cells, which has been used to assay transactivation and dominant negative properties of artificial and natural c-erbAf mutants ( 13, 31 ) . The ability ofG.H. receptor to induce MTV-TREir-CAT was measured versus that of the wild-type c-erbA# l receptor (Fig. 6) . At 100 nM T3, stimulation of CAT activity by the G.H. receptor in HeLa cells transfected with 2 or 20 ,ug of pEXPRESS-G.H. was only two-to threefold. In contrast, stimulation in cells transfected with 2 ,g ofthe wild-type human c-erbAfl vector was -60-fold at 5 nM T3 and 100-fold with 100 nM T3. The ability ofthe G.H. receptor to block wild-type receptor function was studied along with a vector expressing the mutant kindred S receptor. The kindred S cDNA was cloned from a family with generalized resistance to thyroid hormone (7) and can mediate a potent dominant negative effect ( 13) . The kindred S receptor, which has virtually no affinity for T3, does not transactivate the TREir reporter gene and markedly inhibits wild-type receptor function in HeLa cells (Fig. 6) (13) (35) . A single case of a double mutation in exon 9 and exon 10 has also been found ( 10). The mutations that have been characterized all variably affect T3-binding affinity (twofold reduction to complete T3-binding inactivity) and have different potencies as dominant negative proteins on thyroid hormone-regulated reporter genes in transient transfection systems (4, 7-9, 11, 13, 14, 22 The fact that ARG-3 1 -HIS did not by itself lead to dominant negative activity uncovers a functional complexity to the T3-binding domain of c-erbA(3 in vivo. This functional complexity has already been partially elucidated by recent transfection and DNA-binding studies that indicate the existence of thyroid hormone receptor auxiliary proteins (TRAP) that heterodimerize with the (-and a-receptors and potentiate DNA binding and possibly transactivation (31, (36) (37) (38) (39) (40) (41) (42) (43) (44) . These studies imply that heterodimers of (-receptor TRAP or a-receptor TRAP rather than homodimers of receptors transactivate genes. The identity of the TRAP protein or proteins is still under investigation, but very recent work indicates that retinoid X receptors may be members of this group (45) (46) (47) (48) . One portion of the TRAP domain of the rat A-receptor has been determined to lie approximately between codons 280 and 300 (38, 40) , very close to the mutation at codon 31 1. This study suggests that a specific residue in the ligandbinding domain of the (-receptor is critical for a dominant negative function. Although the precise mechanism ofthe dominant negative effect of the GRTH mutations has not been elucidated, it appears that the mutant receptors compete with wild-type receptors at TREs or compete for auxiliary transcription factors ( 13, 14, 18) . The mutations of (-receptor found in GRTH avoid the important heptad repeats of the T3-binding domain that are thought to be required for receptor-protein interactions (34) . Furthermore, these mutations are separated from the TRAP domain, also necessary for such interactions (36) (37) (38) (39) (40) (41) (42) (43) (44) . Therefore, the GRTH mutants can, theoretically, successfully compete with wild-type receptors for TREs and inhibit thyroid hormone action. Identification of the G.H. receptor strongly supports a model for receptor-protein interactions in mediating thyroid hormone action in vivo. If no such interactions were important, the G.H. receptor with an intact DNA-binding domain would have been expected to behave as a potent dominant negative protein, resulting in thyroid hormone resistance in the father and half-sister ofpatient G.H. We speculate that the ARG-3 1 1-HIS mutation perturbs a dimerization or TRAP domain of the c-erbA( receptor, abrogating its ability to compete with wild-type receptor for transcription factors or to form a transcription complex with high affinity for TREs. The crucial structural role of codon 311 in c-erbA(3 must await crystallographic data, which will resolve the putative dimerization and TRAP domains. However, the special role of codon 31 1 in c-erbA(3 structure and function is further suggested by the complete conservation of arginine at this site in the retinoic acid and vitamin D receptors, c-erbA, v-erbA and Rev-erbA (34) . A GRTH mutation at codon 312 reported by Parrilla et al. (9) more modestly affected T3-binding affinity compared with G.H., and this codon is not so strictly conserved among other members of the thyroid/steroid gene superfamily. Future investigations using cloned retinoid X receptors and other possible TRAP factors with assorted TREs in gelshift and transfection assays will be necessary to characterize the range of effects the G.H. mutation has on DNA-binding affinities, heterodimerization, transactivation, and dominant negative function.
A trivial explanation for the lack of dominant negative activity from the G.H. allele would be that the G.H. receptor protein is not produced. This seems extremely unlikely, given that the G.H. receptor synthesized in reticulocyte lysate was quite stable and could be purified after bacterial expression (Samuels, H. H., and F. Su, New York University Medical Center, unpublished data). Furthermore, Meier et al. (13) have demonstrated that a wide range of GRTH receptors are stable in transfected HeLa cells.
Another important conclusion of this study is that it suggests possible molecular heterogeneity to thyroid hormone resistance syndromes. GRTH has been shown to be a genetically homogeneous syndrome. However, the form of PRTH that patient G.H. has cannot be due to the single mutant G.H. allele. One can speculate that the severe pituitary resistance of patient G.H. may be due to a second mutation in the remaining c-erbA3 allele or c-erbAa alleles ofthe thyrotrophs, resulting in a dominant negative mutant, combined with compromised thyroid hormone responsiveness due to a null c-erbAf allele. Although this second putative mutation is predicted to be somatic, we have sequenced multiple clones of the last two exons ofc-erbAa from patient G.H. that correspond to fl-exons 9 and 10, and no mutation was found (data not shown). Furthermore, we have considered the possibility of a germ-line mutation in the promoter of hTSH# (49) and have found no mutation in the +3-to +37-bp segment of this promoter. It is also possible that the putative second somatic mutation may not result in a dominant negative thyroid hormone receptor but may be in a retinoid X receptor gene or a yet to be identified TRAP gene.
Finally, it must be recognized that patient G.H. is unique in her serum levels of thyroid hormones; many other patients diagnosed with PRTH have total thyroxine levels < 20-25 jig/ dl (25, 50) . Although the clinical condition ofPRTH may turn out to be heterogeneous in terms of molecular etiology, c-erbAf defects may be generally involved with different clinical forms of this syndrome. We have found a LEU-325-PHE mutation in a previously published patient with PRTH (24, 51 ) . The original patient with PRTH described by Gershengorn and Weintraub (23) has recently been found to have a common c-erbAf3 mutation (52) . Further clinical and genetic studies will be necessary to explain the molecular basis of the variable clinical forms of PRTH.
